Loxo Oncology Inc (NASDAQ:LOXO) insider Naarden Jacob Van sold 3,082 shares of the business’s stock in a transaction that occurred on Tuesday, July 10th. The shares were sold at an average price of $183.50, for a total value of $565,547.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Naarden Jacob Van also recently made the following trade(s):
- On Wednesday, June 20th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $178.14, for a total value of $549,027.48.
- On Tuesday, May 15th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $137.42, for a total value of $423,528.44.
- On Wednesday, April 25th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $131.23, for a total value of $404,450.86.
Loxo Oncology traded up $5.07, reaching $181.06, during mid-day trading on Wednesday, MarketBeat Ratings reports. 620,109 shares of the company were exchanged, compared to its average volume of 472,329. The firm has a market cap of $5.62 billion, a P/E ratio of -34.02 and a beta of 2.45. Loxo Oncology Inc has a 12-month low of $69.00 and a 12-month high of $208.95.
Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $38.43 million for the quarter, compared to analysts’ expectations of $12.72 million. During the same quarter in the prior year, the company earned ($0.96) EPS. research analysts anticipate that Loxo Oncology Inc will post 0.91 earnings per share for the current year.
LOXO has been the subject of a number of research reports. Morgan Stanley lowered Loxo Oncology from an “overweight” rating to an “equal weight” rating and set a $103.00 price target for the company. in a report on Wednesday, March 21st. They noted that the move was a valuation call. Citigroup boosted their price target on Loxo Oncology to $235.00 and gave the company a “buy” rating in a report on Monday, June 4th. Piper Jaffray Companies initiated coverage on Loxo Oncology in a report on Wednesday, May 30th. They issued an “overweight” rating and a $200.00 price target for the company. ValuEngine upgraded Loxo Oncology from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Finally, JMP Securities boosted their price target on Loxo Oncology from $182.00 to $221.00 and gave the company a “buy” rating in a report on Monday, June 4th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Loxo Oncology currently has an average rating of “Buy” and a consensus target price of $176.40.
Institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP lifted its holdings in Loxo Oncology by 770.1% during the first quarter. Quantbot Technologies LP now owns 931 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 824 shares during the period. IFP Advisors Inc lifted its holdings in Loxo Oncology by 509.6% during the first quarter. IFP Advisors Inc now owns 1,012 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 846 shares during the period. QS Investors LLC purchased a new stake in Loxo Oncology during the fourth quarter worth $118,000. Brown Advisory Inc. purchased a new stake in Loxo Oncology during the first quarter worth $244,000. Finally, Suntrust Banks Inc. purchased a new stake in Loxo Oncology during the first quarter worth $277,000.
Loxo Oncology Company Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.